close
Add to watchlist
Aastrom Biosciences Inc (ASTM) Healthcare, Biotechnology & Drugs
Aastrom Biosciences, Inc. engages in developing autologous cell products for the repair or regeneration of human tissue. Its proprietary tissue repair cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. The company's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. Aastrom's development activities are focused on applying TRC technology to cardiac and vascular tissue regeneration. It focuses on cardiovascular regeneration and is conducting a Phase II clinical trial with dilated cardiomyopathy patients (the IMPACT-DCM clinical trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI clinical trial). The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.04 |
| Volume | 415496 |
| Volume Avg | 278273 |
| 52 Week High | 3.47 |
| 52 Week Low | 1.75 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.90 |
| EPS change Q/Q | 100% |
| EPS change Q/Q Yr ago | 100% |
| EPS change Q/Q next Q est | -18.75% |
| EPS change Y/Y | -100% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.16 |
| EPS next Y est | -0.67 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |